hgoodell retweeted
The deadline to apply for the @CircIntv Assistant Editor Program is TODAY!
If you’re interested in getting involved with the scientific publishing process and working with a great group, consider applying!
@BinitaShahMD @mmamas1973 @DFCapodanno @djc795 @SCAI
The call for nominations for the next class of Assistant Editors for @CircIntv is now open!
Several of our previous Assist Editors have gone to become Editors at other major journals.
More information about the program here:
ahajournals.org/esc
White House Moves to Take Control of N.I.H. Grants nytimes.com/2026/09/20/scien…
Microsoft and OpenAI Workers Worry About ‘Largest Theft of Labor’ in History nytimes.com/2026/09/17/techn…
Another Heart Drug Fails, Shocking Cardiologists nytimes.com/2026/09/04/scien…
hgoodell retweeted
🔥 Hot Line: In #nonobstructiveHCM, there's no outflow obstruction to relieve — so how does aficamten actually work? A prespecified echo substudy of ACACIA-HCM (n=517) at #ESCCongress found improved diastolic function markers vs. placebo. ahajrnls.org/4qLBG66 @SheilaHegde
hgoodell retweeted
For years, hypercontractility in #HCM was assumed to mean stronger myosin. This #ESCCongress piece from Kawana, Ruppel, and Spudich makes the case that it's not strength — it's too many myosin heads freed from their resting "off" state.
That reframe is exactly what led to #mavacamten and #aficamten. Proud of this science coming out of our #ESCCongress + @CircAHA partnership.🫀
The science behind aficamten: #HCM hypercontractility isn't stronger myosin — it's too many myosin heads freed from their resting "off" state. Inhibiting that mechanism provides benefit in HCM even without outflow obstruction, the premise ... #ESCCongress. ahajrnls.org/4xrEPdS
hgoodell retweeted
Sim Pub #ESCCongress & @CircOutcomes
bit.ly/4wSfmJe
Analysis of direct hospital cost savings of POET trial
(switching stable patients w L-sided endocarditis from IV to oral antibiotics as effective as continued IV therapy & shortens hospitalizations) 🧵1/3 👇
@escardio
hgoodell retweeted
Today is the day! Join AHA Journals Editors at #ESCCongress and learn about:
✔️ Topics of interest to the journals
✔️ How best to present your work
✔️ Other tips for submitting a ms
📅 TODAY, Sat, Aug 29 @ 6-8pm CEST
📍Hotel Bayerischer Hof, Konigssaal (King's Hall)
hgoodell retweeted
Do blood pressure programs keep working once trial support ends? In #CRHCP, free medications, incentives, and extra training stopped after year 4 — but the non-physician provider model stayed. From years 4–7, the cardiovascular benefit held... #ESCCongress ahajrnls.org/4wWA1Mw
hgoodell retweeted
🔥 Hot Line: No approved therapy exists for nonobstructive #hypertrophiccardiomyopathy — can a cardiac myosin inhibitor help? In ACACIA-HCM (n=517), 53% of patients on aficamten vs. 14% on placebo met ≥3 of 5 prespecified be... #ESCCongress ahajrnls.org/4gw7reE @MartinMaronMD
hgoodell retweeted
Editorial at #ESCCongress on #DANCODE: statins partly work by maturing vulnerable plaque into dense, stable calcium. So does slowing that calcification help — or remove a marker of stability? In DANCODE, calcified volume fell, but noncalcified plaque wa... ahajrnls.org/4i04Snt
hgoodell retweeted
Today is the day!
Join us at #ESCCongress: "A New Pulse at Circulation: Breakthrough Science with Global Impact" — Fri, Aug 28, 11:00am–12:00pm CEST, Kyiv (Hall B1). @bradleymaronmd and the editorial team share their vision for the journal's next era
ahajrnls.org/46nO9mS
hgoodell retweeted
Is the coronary calcification pathway modifiable? New Hot Line at #ESCCongress + sim pub: in DANCODE (n=398, CAC ≥400 AU), vitamin K2 + D3 slowed 24-mo CAC progression by 52 AU (21%) vs placebo. Not a validated surrogate — outcome trials... ahajrnls.org/4wPfYiP @ADiederichsen
hgoodell retweeted
Join us at #ESCCongress: "A New Pulse at Circulation: Breakthrough Science with Global Impact" — Fri, Aug 28, 11:00am–12:00pm CEST, Kyiv (Hall B1). @bradleymaronmd and the editorial team share their vision for the journal's next era.
Learn more:
ahajrnls.org/46nO9mS
hgoodell retweeted
What does the future of Circulation look like? Incoming Editor-in-Chief @bradleymaronmd shares a vision centered on scientific excellence, innovation, and publishing the highest-impact cardiovascular research for the global cardiovascular community.
@kejoynt @HeartDocSadiya
hgoodell retweeted
Meet AHA Journals Editors at #ESCCongress! Learn about:
✔️ Topics of interest to the journals
✔️ How best to present your work
✔️ Other tips for submitting a ms
📅 Sat, Aug 29 @ 6-8pm CEST
📍Hotel Bayerischer Hof, Konigssaal (King's Hall)
hgoodell retweeted
Wearable Data Economy: Implications of the FDA's 2026 General Wellness Policy @JRGolbus @drkashvigupta @umichcvc
ahajrnls.org/3U6kKuN
hgoodell retweeted
Inside the Journal:
Practice changing. Sometimes surprising. When well-designed, always informative.
Our commitment to clinical trials takes shape today with a Perspective by @texhern. He outlines what we're looking for: relevance to real clinical decisions, reach into the populations where disease actually occurs, rapid learning through adaptive design, and rigor that never bends.
This @CircAHA is ready to lead the way in cardiovascular clinical trial research. Read the Perspective: ahajournals.org/doi/full/10.…
@American_Heart | #Cardiology #Circulation #ClinicalTrials
ALT Circulation journal cover for Volume 154, Number 7, August 18, 2026, with the Perspectives listing for 'Pursuing Clinical Trials "Adaptable" to the Moment' by AF Hernandez circled in yellow, beside a graphic reading 'Inside the Journal: Adrian F. Hernandez, MD, MHS, Deputy Editor, Clinical Trials,' with a circular red-framed headshot of Dr. Hernandez, a smiling man wearing a navy suit and gold tie.